What is Arcus Biosciences Inc Quarterly Revenue?

Arcus Biosciences Inc Quarterly Revenue Arcus Biosciences Inc Jun-2026 Quarterly Revenue is $41 Million which is growth of -74.4% YoY.

What is Arcus Biosciences Inc Quarterly Net Profit?

Arcus Biosciences Inc Quarterly Net Profit Arcus Biosciences Inc Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 0% YoY.

What is Arcus Biosciences Inc Annual Revenue?

Arcus Biosciences Inc Annual Revenue Arcus Biosciences Inc Dec-2025 Annual Revenue is $247 Million which is growth of -4.3% YoY.

What is Arcus Biosciences Inc Annual Net Profit?

Arcus Biosciences Inc Annual Net Profit Arcus Biosciences Inc Dec-2025 Annual Net Profit is $-353 Million which is growth of -24.7% YoY.

What is Arcus Biosciences Inc Total Shareholders Fund?

Arcus Biosciences Inc Total Shareholders Fund Arcus Biosciences Inc Dec-2025 Total Shareholders Fund is $631 Million which is growth of 30.1% YoY.

What is Arcus Biosciences Inc Total Assets?

Arcus Biosciences Inc Total Assets Arcus Biosciences Inc Dec-2025 Total Assets is $1,139 Million which is growth of -1.0% YoY.

What is Arcus Biosciences Inc Book Value Per Share?

Arcus Biosciences Inc Book Value Per Share Arcus Biosciences Inc Book Value Per Share is $3 which is growth of -24.1% YoY.

What is Arcus Biosciences Inc ROE?

Arcus Biosciences Inc ROE Arcus Biosciences Inc ROE is 0% which is growth of 0% YoY.

What is Arcus Biosciences Inc Cash From Operating Activity?

Arcus Biosciences Inc Cash From Operating Activity Arcus Biosciences Inc Dec-2025 Cash From Operating Activity is $-482 Million which is growth of -183.5% YoY.

What is Arcus Biosciences Inc Net Cash Flow?

Arcus Biosciences Inc Net Cash Flow Arcus Biosciences Inc Dec-2025 Net Cash Flow is $72 Million which is growth of 213.0% YoY.

Arcus Biosciences Inc

XNYS: RCUS

Momentum Trap

Download real time

-0.70(-3.07%)

30.31% Fall from 52W High

1.4M

XNYS Volume

XNYS 16 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Board Meeting

The next board meeting for Arcus Biosciences Inc is on 20 Oct 2026 for the purpose of Arcus Biosciences Investor EventSee details

Arcus Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Arcus Biosciences Inc share price target, revenues, EPS, net income and more

Arcus Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

NEGATIVE
Quarterly Revenue Arcus Biosciences Inc Jun-2026 Quarterly Revenue is $41 Million which is growth of -74.4% YoY.
NEUTRAL
Quarterly Net Profit Arcus Biosciences Inc Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 0% YoY.

Arcus Biosciences Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	41	17	33	26	160	28	26	48	39	145	31	32	29
CostOfRevenue_Q Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
GrossProfit_Q Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
OEXPNS_Q Operating Exp. ⌄	137	151	147	168	168	150	129	153	145	141	122	112	112
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	24	29	26	27	29	28	28	30	30	32	29	30	28
ResearchAndDevlopmentExpenses_Q RnD Exp.	113	122	121	141	139	122	101	123	115	109	93	82	84
OP_Q Operating Profit	-96	-134	-114	-142	-8	-122	-103	-105	-106	4	-91	-80	-83
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	5	6	8	7	8	10	10	13	13	12	11	11	9
Others_Q Other Interest Earned	8	9	10	10	10	11	12	14	13	13	11	12	9
IntExpNonOperating_Q Interest Exp. Non Operating	3	3	2	3	2	1	2	1		1		1
PBT_Q Profit Before Tax	-91	-128	-106	-135		-112	-94	-92	-93	-4	-80	-69	-74
TAX_Q Tax							1				1	2	1
NICommonStockholders_Q Net Income Common Stockholders ⌄	-91	-128	-106	-135		-112	-94	-92	-93	-4	-81	-71	-75
NP_Q Net Profit	-91	-128	-106	-135		-112	-94	-92	-93	-4	-81	-71	-75
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-91	-128	-106	-135		-112	-95	-92	-93	-4	-81	-71	-75
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-91	-128	-106	-135		-112	-94	-92	-93	-4	-81	-71	-75
EPS_Q Basic EPS	-0.7	-1	-0.9	-1.3		-1.1	-1	-1	-1	-0.1	-1.1	-0.9	-1
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.7	-1	-0.9	-1.3		-1.1	-1	-1	-1	0.2	-1.1	-0.9	-1
SHARE_Q Number Of Shares End	126.1	125.4	118.5	106.5	106.1	98.4	91.6	91.4	91.1	86.2	75.2	74.6	73.2
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-91	-128	-106	-135		-112	-94	-92	-93	-4	-81	-71	-75
NormalizedIncome_Q Normalized Income	-76	-108	-91	-121	11.9	-96	-81.6	-73	-73	36	-66.8	-56.8	-60.8
InterestIncome_Q Interest Income	8	9	10	10	10	11	12	14	13	13	11	12	9
INT_Q Interest	3	3	2	3	2	1	2	1		1		1
NetInterestIncome_Q Net Interest Income	5	6	8	7	8	10	10	13	13	12	11	11	9
EBIT_Q EBIT	-96	-134	-114	-142	-8	-122	-104	-105	-106	-16	-91	-80	-83
EBITDA_Q EBITDA	-93	-132	-111	-140	-6	-119	-101	-103	-104	-13	-88	-79	-81
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	3	2	3	2	2	3	3	2	2	3	3	1	2
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-91	-128	-106	-135		-112	-94	-92	-93	-4	-81	-71	-75
NormalizedEBITDA_Q Normalized EBITDA	-85	-123	-101	-130	4	-108	-89	-89	-91	20	-77	-67	-72

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Arcus Biosciences Inc competitor comparison and performance snapshot within industry

Arcus Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Annual Revenue Arcus Biosciences Inc Dec-2025 Annual Revenue is $247 Million which is growth of -4.3% YoY.
NEGATIVE
Annual Net Profit Arcus Biosciences Inc Dec-2025 Annual Net Profit is $-353 Million which is growth of -24.7% YoY.

Arcus Biosciences Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
SR_A Total Rev. Ann. ⌄	30.2%	26.1%		247	258	117	112	382.9	77.5	15	8.4	1.4
TotalOperatingRevenues_A Operating Rev. Ann.	30.2%	26.1%	117	247	258	117	112	382.9	77.5	15	8.4	1.4
CostOfRevenue_A Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-		-	-	-	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	17.3%	25.7%	603	633	568	457	392	328.6	201.8	103.7	63.2	54.9	18.2
OP_A Operating Profit Ann.	-	-	-486	-386	-310	-340	-280	54.3	-124.2	-88.7	-54.9	-53.4	-18.2
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	33.1%	88.1%	26	33	48	39	14	0.4	1.4	5.2	4.9	0.4	0.2
Others_A Other Interest Earned Ann.	36.8%	96.5%	37	41	52	41	16	0.7	1.4	5.2	4.9	0.4	0.2
IntExpNonOperating_A Interest Exp. Non Operating Ann.	58.7%	-	11	8	4	2	2	0.3	-	-	-	-	-
OtherExpenses_A Other Exp. Ann.	-	-		-	-20	-	-	-	-	-1.2	0.3	-	-
PBT_A PBT Ann.	-	-	-460	-353	-283	-301	-266	54.6	-122.9	-84.7	-49.6	-53.1	-18
TAX_A Tax Ann.	-17.8%	-			1	6	1	1.8	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-460	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
NP_A Net Profit Ann.	-	-	-460	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-460	-353	-284	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-460	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
EPS_A EPS Ann.	-	-		-3.3	-3.1	-4.2	-3.7	0.8	-2.2	-1.9	-1.4	-2.2	-0.7
DilutedEPS_A Diluted EPS Ann.	-	-		-3.3	-3.1	-4.2	-3.7	0.7	-2.2	-1.9	-1.4	-2.2	-0.7
SHARE_Q Number Of Shares End	17.7%	13.3%		118.5	91.6	75.2	72.7	70.4	63.6	44.1	42.3	24.6	-
TotalExpenses_A Total Exp. Ann.	17.3%	25.7%		633	568	457	392	328.6	201.8	103.7	63.2	54.9	18.2
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-460	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
NormalizedIncome_A Normalized Income Ann.	-	-	-396	-293	-208.2	-249.3	-215.7	105.6	-101.7	-75.7	-47	-52.6	-17.9
InterestIncome_A Interest Income Ann.	36.8%	96.5%	37	41	52	41	16	0.7	1.4	5.2	4.9	0.4	0.2
INT_A Interest Ann.	58.7%	-	11	8	4	2	2	0.3	-	-	-	-	-
EBITDA_A EBITDA Ann.	-	-	-476	-376	-321	-332	-274	58.1	-120	-86.3	-50.9	-50.8	-16.9
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	18.6%	18.9%	10	10	10	8	6	3.8	4.2	3.6	3.7	2.6	1.3
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-460	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-439	-335	-249	-291	-258	58.8	-120.7	-85.1	-52.4	-50.8	-16.9

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

-4.3%

2Y CAGR

45.3%

3Y CAGR

30.2%

5Y CAGR

26.1%

7Y CAGR

62.1%

Total Revenue Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

11.4%

2Y CAGR

17.7%

3Y CAGR

17.3%

5Y CAGR

25.7%

7Y CAGR

39%

Operating Expenses Annual Cr growth is lower than historical averages.

Arcus Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Arcus Biosciences Inc Dec-2025 Total Shareholders Fund is $631 Million which is growth of 30.1% YoY.
NEGATIVE
Total Assets Arcus Biosciences Inc Dec-2025 Total Assets is $1,139 Million which is growth of -1.0% YoY.

Arcus Biosciences Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
TA_A Total Assets Ann. ⌄	-5.4%	8.1%	1,139	1,150	1,095	1,345	1,591.9	772.3	203.1	274.9	190.5	109.7
CA_A Total Current Assets Ann.	-1.9%	6.5%	1,007	1,016	831	1,067	1,261.8	735.8	192.7	259	176.9	99.7
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	-0.9%	6.1%	981	978	759	1,009	499.3	728.7	188.3	256.5	175.7	98.9
Receivables_A Change In Account Receivables Ann.	-28.1%	56.6%	16	25	42	43	746.8	1.7	0.1	0.1	0	0.4
Inventories_A Inventories Ann.	-	-	-	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	-12.6%	12.7%	10	13	30	15	15.6	5.5	4.3	2.3	1.1	0.4
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-22%	29.3%	132	134	264	278	330.2	36.5	10.4	16	13.6	10
NetPPE_A Net PPE Ann.	4.6%	11.1%	40	47	51	35	137.4	23.6	9.3	11.1	11.2	8.6
InvestmentsAndAdvances_A Investments & Advances Ann.	-39.2%	35.3%	29	14	107	129	182	6.4		4.4	0.7	1
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-17.9%	57.5%	63	73	106	114	10.7	6.5	1.1	0.5	1.7	0.4
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	-9.6%	13.5%	508	665	633	688	750.5	270	39.3	40	36.6	10.2
CL_A Total Current Liabilities Ann.	6.2%	13.7%	231	226	184	193	166.1	121.7	22.7	16.9	12.7	5.6
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	19.8%	30.6%	165	115	79	96	64	43.5	14.2	9.1	7	4.9
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-	-	13	12	11	-	-	-	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-28.8%	-14%	35	85	91	97	102	74.6	7	6.3	5	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	38%	18	14	3	-	0.1	3.6	1.5	1.6	0.8	0.7
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-17.6%	13.3%	277	439	449	495	584.4	148.3	16.6	23.1	23.9	4.7
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-	45.5%	99	48	-	-	116.9	15.2	-	-	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	-1.3%	4.7%	631	485	462	657	841.5	502.3	163.8	234.9	153.9	-20
EQCAP_A Equity Share Capital Ann.	-1.3%	4.7%	631	485	462	657	841.5	502.3	163.8	234.9	153.9	99.5
CapitalStock_A Capital Stock Ann.	20.6%	-	2,116	1,617	1,311	1,206	0	0				119.5
RetainedEarnings_A Retained Earnings Ann.	-	-	-1,485	-1,132	-849	-542	-275.4	-328.2	-205.3	-122.8	-73.2	-20.2
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	-	-		-7	-1.3	0	0.1	-0.1	-0	-0
TotalCapitalization_A Total Capitalization Ann.	3.6%	7.8%	730	533	462	657	841.5	502.3	163.8	234.9	153.9	99.5
TangibleAssets_A Tangible Assets Ann.	-1.3%	4.7%	631	485	462	657	841.5	502.3	163.8	234.9	153.9	99.5
WC_A Working Capital Ann.	-3.9%	4.8%	776	790	647	874	1,095.7	614.2	170	242	164.1	94.1
InvestedCapital_A Invested Capital Ann.	3.6%	7.8%	730	533	462	657	841.5	502.3	163.8	234.9	153.9	-20
TangibleBookValue_A Tangible Book Value Ann.	-1.3%	4.7%	631	485	462	657	841.5	502.3	163.8	234.9	153.9	-20
Borrowings_A Borrowings Ann.	-	49.1%	112	60	11	-	116.9	15.2	-	-	-	-
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	19.8%	14%	125.3	92.2	75.5	72.9	70.8	65.1	45.9	44.5	42.6	42.6
SHARE_Q Number Of Shares End	17.7%	13.3%	118.5	91.6	75.2	72.7	70.4	63.6	44.1	42.3	24.6	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

-1%

2Y CAGR

3Y CAGR

-5.4%

5Y CAGR

8.1%

7Y CAGR

22.5%

Total Assets Annual is falling faster than historical averages.

Total Current Liabilities Ann.

1Y CHG

2.2%

2Y CAGR

12%

3Y CAGR

6.2%

5Y CAGR

13.7%

7Y CAGR

45.3%

Total Current Liabilities Annual Cr growth is lower than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

30.1%

2Y CAGR

16.9%

3Y CAGR

-1.3%

5Y CAGR

4.7%

7Y CAGR

15.2%

Total ShareHolders Funds Annual growth is higher than historical averages.

Arcus Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Arcus Biosciences Inc Book Value Per Share is $3 which is growth of -24.1% YoY.
NEUTRAL
ROE Arcus Biosciences Inc ROE is 0% which is growth of 0% YoY.

Arcus Biosciences Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
ROA_A RoA Ann. %	-	-	-	-25.21%	-25.16%	-18.18%	4.47%	-25.19%	-35.44%	-21.31%	-35.37%	-16.38%
ROE_A ROE Ann. %	-	-	-	-59.77%	-54.87%	-35.64%	7.86%	-36.89%	-42.48%	-25.51%	-79.30%	-
ROIC_Q ROIC %	-	-	-	-17.5	-17.9	-11	36	-9.7	-10.3	-5.5	-8.7	-
OPMPCT_A OPM Ann. %	-	-	-156.28%	-120.16%	-290.60%	-250.00%	14.17%	-160.27%	-591.39%	-656.76%	-3,782.09%	-
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0.2	0.1	0.1	0.3	0.2	0.1	0	0	-
WCTO_A Working Capital Turnover Ann.	44.2%	24.6%	0.3	0.3	0.2	0.1	0.4	0.1	0.1	0	0
QuickRatio_A Quick Ratio Ann.	-	-	-	4.4	4.4	5.5	7.5	6	8.3	15.2	13.8	17.9
CRATIO_A Current Ratio Ann.	-	-	-	4.5	4.5	5.5	7.6	6.1	8.5	15.3	13.9	18
IC_A Interest Coverage Ratio Ann.	-	-	-	-69.8	-149.5	-132	211.2	-	-	-	-	-
LTDE_A LT Debt To Equity Ann.	-	-	-	0.1	-	-	0.1	0	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Arcus Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Arcus Biosciences Inc Dec-2025 Cash From Operating Activity is $-482 Million which is growth of -183.5% YoY.
POSITIVE
Net Cash Flow Arcus Biosciences Inc Dec-2025 Net Cash Flow is $72 Million which is growth of 213.0% YoY.

Arcus Biosciences Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-482	-170	-306	438	-256.2	111.2	-73.5	-43	-25.1	-12.9
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-353	-283	-307	-267	52.8	-122.9	-84.7	-49.6	-53.1	-18
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	18.6%	18.9%	10	10	8	6	3.8	4.2	3.6	3.7	2.6	1.3
DepreciationAndAmortization_A Depreciation And Amortization Ann.	18.6%	18.9%	10	10	8	6	3.8	4.2	3.6	3.7	2.6	1.3
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	-2.6%	22.4%	60	76	73	65	54.5	21.8	9	3.9	0.5	0.1
OtherNonCashItems_A Other Non Cash Items Ann.	-10.1%	-	8	10	10	11	3.5	-	-	-0.2	-0.1	-
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-194	22	-71	623	-375.6	208.1	0.1	1.3	24.6	3.6
ChangeInReceivables_A Change In Receivables Ann.	-76.6%	-	9	28	15	704	-17.1	-0.9	-0.1	-0.1	0.4
ChangeInInventory_A Change In Inventory Ann.	-	-	-	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	44.2%	-2.8%	24	3	-1	8	13.7	27.6	5.2	3.4	1.3	4.4
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	35.7%	-	5	22	-14	2	3.3	-5.4	-0.6	-0.1	-0	-0.2
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-27.5%	-2.8%	8	25	-3	21	-1.8	9.2	0.1	0	-0.1	0.7
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-240	-56	-68	-112	-367.9	178.4	-2.5	-0.8	23.8	-0.6
CFI_A Cash from Investing Act. Ann. ⌄	-	-	66	-84	194	-413	-3.9	-434.4	59.2	-113.4	-49.1	-38.9
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-2	-6	-24	-6	-26.1	-3.1	-1.9	-3.7	-5.5	-4.1
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-2	-6	-24	-6	-26.1	-3.1	-1.9	-3.7	-5.5	-4.1
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-			-1
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-			-1
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-1,076	-1,043	-788	-1,241	-718.9	-739.7	-247.8	-261.6	-96.8	-33.8
SaleOfInvestment_A Sale Of Investment Ann.	11%	30%	1,144	965	1,006	837	741.1	308.4	308.9	151.9	53.3
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	145.5%	2.2%	488	277	33	33	237.3	438.7	1.1	129.1	107.4	70.1
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	49	47	-	-	-	-	-	-	-	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	49	47	-	-	-	-	-	-	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-0.2%	429	228	25		220.2	433.7	1.2	125.1	-
CommonStockIssuance_A Common Stock Issuance Ann.	-	-0.2%	429	228	25		220.2	433.8	1.2	125.1	-
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-0	-0.1	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-	-7	-	10	5	-	-	-0.1	-0.4	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	2.5%	5.3%	225	153	130	209	150.9	173.6	58.1	71.1	98.4	65.2
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	7.5%	-9%	72	23	-79	58	-22.7	115.5	-13.1	-27.4	33.3	18.3
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	0.4%	21.4%	153	130	209	151	173.6	58.1	71.3	98.4	65.2	46.9
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-			-	3	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	7	1	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-2	-6	-24	-12	-26.1	-3.1	-1.9	-3.7	-5.5	-4.1
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-0.2%	429	228	25		220.2	433.8	1.2	125.1	106.9	69.8
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	49	47	-	-	-	-	-	-	-	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-	-	-	-	-	-	-	-	-	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-0	-0.1	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-484	-176	-330	426	-282.3	108.1	-75.4	-46.7	-30.6	-17

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Investing Act. Ann.

2Y CAGR

-41.7%

Cash from Investing Activity Annual growth is stable compared to historical averages.

Cash from Financing Act. Ann.

1Y CHG

76.2%

2Y CAGR

284.6%

3Y CAGR

145.5%

5Y CAGR

2.2%

7Y CAGR

20.9%

Cash from Financing Annual Activity growth is stable compared to historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

30.31% Fall from 52W High

Arcus Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Arcus Biosciences Inc - Forecaster

Forecaster Analyst Estimates for Arcus Biosciences Inc share price target, revenues, EPS, net income and more

Arcus Biosciences Inc - Earnings Report - Quarterly Results

Arcus Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Arcus Biosciences Inc Jun-2026 Quarterly Revenue is $41 Million which is growth of -74.4% YoY.

Quarterly Net Profit Arcus Biosciences Inc Jun-2026 Quarterly Net Profit is $-91 Million which is growth of 0% YoY.

Arcus Biosciences Inc - Competitors/Peers

Arcus Biosciences Inc competitor comparison and performance snapshot within industry

Arcus Biosciences Inc - Earnings Report - Annual Results

Arcus Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Arcus Biosciences Inc Dec-2025 Annual Revenue is $247 Million which is growth of -4.3% YoY.

Annual Net Profit Arcus Biosciences Inc Dec-2025 Annual Net Profit is $-353 Million which is growth of -24.7% YoY.

Arcus Biosciences Inc - Balance Sheet

Arcus Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Arcus Biosciences Inc Dec-2025 Total Shareholders Fund is $631 Million which is growth of 30.1% YoY.

Total Assets Arcus Biosciences Inc Dec-2025 Total Assets is $1,139 Million which is growth of -1.0% YoY.

Arcus Biosciences Inc - Ratios

Arcus Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Arcus Biosciences Inc Book Value Per Share is $3 which is growth of -24.1% YoY.

ROE Arcus Biosciences Inc ROE is 0% which is growth of 0% YoY.

Arcus Biosciences Inc - Cash Flow

Arcus Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Arcus Biosciences Inc Dec-2025 Cash From Operating Activity is $-482 Million which is growth of -183.5% YoY.

Net Cash Flow Arcus Biosciences Inc Dec-2025 Net Cash Flow is $72 Million which is growth of 213.0% YoY.